Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

U.S. high-yield corporate bonds should offer an attractive investment opportunity in 2025, thanks to the economy’s strong growth and potentially supportive business policies, Lombard Odier said.

Plans to flatten and replace eyesore buildings next to one of Kent's most popular roadside cafes have been given the green ...

"It's great to be in Connellsville," Nate Morgan told those attending the ribbon-cutting ceremony Tuesday for The River's ...

The Australian sharemarket opened higher, with Wall Street fluctuating overnight as investors await the release of US ...

Nevertheless, growth stocks outperformed value stocks in 2024, and investors anticipate that trend will continue as the ...

This week, we get a fresh jolt of energy, as SZA and Lamar make way for two blockbuster debuts. Lil Baby enters the chart at No. 1 with WHAM — an acronym for "Who Hard As Me," not a tribute to the duo ...